Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of intralesional administration of REOLYSIN [reovirus] for the treatment of patients with histologically confirmed recurrent malignant gliomas

Next Previous
X
Search
Trial Profile

A phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of intralesional administration of REOLYSIN [reovirus] for the treatment of patients with histologically confirmed recurrent malignant gliomas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncolytics Biotech

    • Most Recent Events

    • 17 Apr 2015 According to an Oncolytics Biotech media release, the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for pelareorep [Reolysin], for the treatment of malignant glioma. The Company had applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages.
    • 23 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top